Condition
IBD-unclassified (IBD-U)
Total Trials
3
Recruiting
3
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Recruiting3
Clinical Trials (3)
Showing 3 of 3 trials
NCT07245394Recruiting
Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)
NCT06954311Recruiting
Therapeutic Drug Monitoring for Biological Therapy in Pediatric Inflammatory Bowel Disease
NCT06655415Recruiting
Family Members At INcreased-risk for Developing Inflammatory Bowel Disease
Showing all 3 trials